Can a serotonin‑norepinephrine reuptake inhibitor be used safely in a patient with REM‑sleep behavior disorder?

SNRIs Should Generally Be Avoided or Discontinued in Patients with REM Sleep Behavior Disorder

If a patient with RBD requires antidepressant therapy, SNRIs should be discontinued and replaced with bupropion, which has a lower serotonergic profile and does not exacerbate RBD. 1

The Evidence Against SNRIs in RBD

Drug-Induced RBD from Serotonergic Agents

The 2023 American Academy of Sleep Medicine clinical practice guideline explicitly addresses this issue under "drug-induced/exacerbated RBD" 1. The guideline makes a conditional recommendation for drug discontinuation when serotonergic antidepressants (including SNRIs) are causing or worsening RBD symptoms. This represents the highest-quality guidance available on this specific question.

Key points from the guideline:

• SNRIs are among the most common medications that induce or exacerbate RBD, particularly in patients younger than 50 years 1
• Decreasing or discontinuing an SNRI may improve dream enactment, though it often doesn't fully eliminate symptoms and may take several months for improvement 1
• The guideline specifically recommends switching to bupropion for patients who still require antidepressant therapy, as it has a lower serotonergic profile 1

Quantitative Evidence of SNRI-Induced REM Sleep Without Atonia

Recent research provides compelling quantitative data on this relationship. A 2026 study analyzing 1,474 polysomnographies found that patients on SNRI monotherapy had a 6.66% increase in REM sleep without atonia (RSWA%) compared to medication-free patients (p < 0.001) 2. This was actually higher than the 3.39% increase seen with SSRIs. Notably, patients taking both SSRIs and SNRIs had a 10.44% increase in RSWA% 2.

This study is particularly important because it:

• Used objective polysomnographic measurements rather than subjective reports
• Included both chin and upper extremity EMG for comprehensive RSWA quantification
• Represents the largest study to quantify RSWA% by antidepressant class

Case Reports and Clinical Observations

A 2017 case report documented duloxetine (an SNRI) directly inducing typical RBD in a 62-year-old woman 3. The symptoms completely ceased 37 days after discontinuation, providing clear temporal evidence of causation. This appears to be the first documented case of duloxetine-induced RBD 3.

A 2006 review explicitly states that "serotonergic synaptic reuptake inhibitors and noradrenergic antagonists can induce or aggravate RBD symptoms and should be avoided in patients with RBD" 4. The review recommends systematic follow-up when these agents are prescribed to at-risk patients.

Clinical Algorithm for Management

Step 1: Assess the Clinical Situation

• Is the SNRI essential for the patient's psychiatric condition?
• How severe is the RBD (frequency of episodes, injury risk)?
• How long has the patient been on the SNRI?

Step 2: If SNRI Can Be Discontinued

• Discontinue the SNRI in coordination with the prescribing psychiatrist/primary care provider 1
• Warn the patient that improvement may take several months 1
• Implement bedroom safety measures immediately (lower mattress, pad furniture corners, remove firearms, consider separate sleeping arrangements) 1

Step 3: If Antidepressant Therapy Must Continue

• Switch to bupropion, which has minimal serotonergic activity and does not exacerbate RBD 1
• Coordinate this change carefully with the prescribing provider to avoid withdrawal or psychiatric decompensation

Step 4: If RBD Persists After SNRI Discontinuation

• Reclassify as isolated RBD or secondary RBD (if underlying neurodegenerative disease present) 1
• Initiate treatment with:
  • First-line: Melatonin 3 mg at bedtime, titrate up by 3 mg increments to 15 mg as needed 1
  • Alternative: Clonazepam 0.25-1.0 mg at bedtime (but use cautiously in older adults due to Beers Criteria concerns) 1

Important Caveats

Timing Considerations

The guideline notes that RBD would be expected to emerge within weeks or months (not years) after starting an inciting agent 1. If a patient has been taking an SNRI uneventfully for years before RBD develops, carefully weigh the risks and benefits of discontinuation, as the SNRI may not be the primary cause.

Incomplete Resolution

Even after SNRI discontinuation, many patients continue to have some degree of dream enactment 1. This suggests that the SNRI may have unmasked underlying RBD rather than being the sole cause. These patients require ongoing RBD treatment.

Avoid Combination Serotonergic Therapy

The combination of SSRI + SNRI showed the highest RSWA% increase (10.44%) in quantitative studies 2. Never combine serotonergic antidepressants in patients with RBD or at risk for RBD.

Tricyclic Antidepressants Are Also Problematic

While the question focuses on SNRIs, note that tricyclic antidepressants can also induce RBD 4. However, the 2026 study found that TCAs did not increase RSWA% in the same way as SSRIs/SNRIs 2, suggesting a more complex relationship.

Bottom Line for Clinical Practice

SNRIs are not safe in patients with established RBD and should be discontinued when possible. The evidence is clear and consistent across guidelines, quantitative polysomnographic studies, and case reports. When antidepressant therapy is necessary, bupropion is the preferred alternative. This recommendation prioritizes patient safety (preventing injury from violent dream enactment) and quality of life (reducing sleep disruption for both patient and bed partner).